Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cladribine in RRMS
NCT00213135Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Apr 2005
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cladribine in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by EMD Serono. Primary endpoint: Annualized Qualifying Relapse Rate at 96 weeks. Started Apr 2005; status: completed.
02
Drugs
cladribine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00213135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00213135.